Nay Lui Saw

Nay Lui Saw

Auto-generated profile, based on publicly available information

Nay Lui Saw

Stanford Behavioral and Functional Neuroscience Laboratory, Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2016 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
MDMarie-Hélène Disatnik
Marie-Hélène Disatnik
AJAmit U. Joshi
Amit U. Joshi
NSNay L. Saw
Nay L. Saw
MSMehrdad Shamloo
Mehrdad Shamloo
BLBlair R. Leavitt
Blair R. Leavitt
DMDaria Mochly-Rosen
Daria Mochly-Rosen
Huntington’s disease (HD) is a rare genetic disease caused by expanded polyglutamine repeats in the huntingtin protein resulting in selective neuronal loss. Although genetic testing readily identifies those who will be affected, current pharmacological treatments do not prevent or slow down disease progression. A major challenge is the slow clinical progression and the inability to biopsy the affected tissue, the brain, making it difficult to design short and effective proof of concept clinical trials to assess treatment benefit. In this study, we focus on identifying peripheral biomarkers that correlate with the progression of the disease and treatment benefit. We recently developed an inhibitor of pathological mitochondrial fragmentation, P110, to inhibit neurotoxicity in HD. Changes in levels of mitochondrial DNA (mtDNA) and inflammation markers in plasma, a product of DNA oxidation in urine, mutant huntingtin aggregates, and 4-hydroxynonenal adducts in muscle and skin tissues were all noted in HD R6/2 mice relative to wild-type mice. Importantly, P110 treatment effectively reduced the levels of these biomarkers. Finally, abnormal levels of mtDNA were also found in plasma of HD patients relative to control subjects. Therefore, we identified several potential peripheral biomarkers as candidates to assess HD progression and the benefit of intervention for future clinical trials.

1 October 2021 in Neurobiology of Aging
Verified
Journal Article
Closed access
AEAndrew K. Evans
Andrew K. Evans
HPHeui Hye Park
Heui Hye Park
NSNay Lui Saw
Nay Lui Saw
KSKratika Singhal
Kratika Singhal
GOGaku Ogawa
Gaku Ogawa
MSMehrdad Shamloo
Mehrdad Shamloo